Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 97-108

  Du, Dan ^a   Yan, Jun ^a   Ren, Jinhong ^a   Lv, Haining ^a   Li, Yong ^a   Xu, Song ^a   Wang, Yadan ^a   Ma, Shuanggang ^a   Qu, Jing ^a   Tang, Weibin ^a   Hu, Zhuowei ^a   Yu, Shishan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; AMINO ACID; CARBOHYDRATE; GLYCYRRHIZIC ACID DERIVATIVE; HIGH MOBILITY GROUP B1 PROTEIN; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART PROTECTION; IN VITRO STUDY; MALE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; SURVIVAL RATE;

ACUTE DISEASE; ANIMALS; CELL LINE; CHRONIC DISEASE; DOXORUBICIN; GLYCYRRHIZIC ACID; HEART FAILURE; HMGB1 PROTEIN; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872287041     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301248y     Document Type: Article

References (36)

1. Lindenfield, J. Excutive summary: 2010 HFSA comprehensive practice guideline J. Card. Failure 2010, 16, 475-539
2. Jessup, M.; Abraham, W. T.; Casey, D. E.; Feldman, A. M.; Francis, G. S.; Ganiats, T. G.; Konstam, M. A.; Mancini, D. M.; Rahko, P. S.; Silver, M. A.; Stevenson, L. W.; Yancy, C. W. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 2009, 119, 1977-2016
3. McMurray, J. J.; Pfeffer, M. A. Heart failure Lancet 2005, 365, 1877-1889
4. Lloyd-Jones, D.; Adams, R.; Carnethon, M.; De Simone, G.; Ferguson, T. B.; Flegal, K.; Ford, E.; Furie, K.; Go, A.; Greenlund, K.; Haase, N.; Hailpern, S.; Ho, M.; Howard, V.; Kissela, B.; Kittner, S.; Lackland, D.; Lisabeth, L.; Marelli, A.; McDermott, M.; Meigs, J.; Mozaffarian, D.; Nichol, G.; O'Donnell, C.; Roger, V.; Rosamond, W.; Sacco, R.; Sorlie, P.; Stafford, R.; Steinberger, J.; Thom, T.; Wasserthiel-Smoller, S.; Wong, N.; Wylie-Rosett, J.; Hong, Y. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2009, 119, e21-e181
5. Jiang, B. B.; Liao, R. The paradoxical role of inflammation in cardiac repair and regeneration J. Cardiovasc. Transl. Res. 2010, 3, 410-416
6. Yang, H.; Wang, H. C.; Czura, C. J.; Tracey, K. J. The cytokine activity of HMGB1 J. Leukocyte Biol. 2005, 78, 1-8
7. Rosenberg, H. F.; Oppenheim, J. J. Interview with Dr. Maurizio C. Capogrossi regarding pivotal advance: high-mobility group box 1 protein-a cytokine with a role in cardiac repair J. Leukocyte Biol. 2007, 81, 38-40
8. Palumbo, R.; Sampaolesi, M.; De Marchis, F.; Tonlorenzi, R.; Colombetti, S.; Mondino, A.; Cossu, G.; Bianchi, M. E. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation J. Cell Biol. 2004, 164, 441-449
9. Mitola, S.; Belleri, M.; Urbinati., C.; Coltrini, D.; Sparatore, B.; Pedrazzi, M.; Melloni, E.; Presta, M. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine J. Immunol. 2006, 176, 12-15
10. Limana, F.; Gemani, A.; Zacheo, A.; Kajstura, J.; Di Carlo, A.; Borsellino, G.; Leoni, O.; Palumbo, R.; Battistini, L.; Rastaldo, R.; Müller, S.; Pompilio, G.; Anversa, P.; Bianchi, M. E.; Capogrossi, M. C. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infraction via enhanced cardiac C-kit+ cell proliferation and differentiation Circ. Res. 2005, 97, e73-e83
11. Germani, A.; Limana, F.; Capogrossi, M. C. Pivotal advances: high-mobility group box 1 protein-a cytokine with a role in cardiac repair J. Leukocyte Biol. 2007, 81, 41-45
12. Li, W.; Sama, A. E.; Wang, H. C. Role of HMGB1 in cardiovascular diseases Curr. Opin. Pharmacol. 2006, 6, 130-135
13. Li, J.; Kokkola, R.; Tabibzadeh, S.; Yang, R.; Ochani, M.; Qiang, X.; Harris, H. H.; Czura, C. J.; Wang, H. C.; Ulloa, L.; Wang, H.; Warren, H. S.; Moldawer, L. L.; Fink, M. P.; Andersson, U.; Tracey, K. J.; Yang, H. Structure basis for the proinflammatory cytokine activity of high mobility group box 1 Mol. Med. 2003, 9, 37-45
14. Yang, H.; Ochani, M.; Li, J.; Qiang, X.; Tanovic, M.; Harris, H. E.; Susarla, S. M.; Ulloa, L.; Wang, H.; DiRaimo, R.; Czura, C. J.; Wang, H.; Roth, J.; Warren, H. S.; Fink, M. P.; Fenton, M. J.; Andersson, U.; Tracey, K. J. Reversing established sepsis with antagonists of endogenous high-mobility group box1 Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 296-301
15. Dumitriu, I. E.; Baruah, P.; Manfredi, A. A.; Bianchi, M. E.; Rovere-Querini, P. HMGB1: guiding immunity from within Trends. Immunol. 2005, 26, 381-387
16. Andrassy, M.; Volz, H. C.; Igwe, J. C.; Funke, B.; Eichberger, S. N.; Kaya, Z.; Buss, S.; Autschbach, F.; Pleger, S. T.; Lukic, I. K.; Bea, F.; Hardt, S. E.; Humpert, P. M.; Bianchi, M. E.; Mairbäurl, H.; Nawroth, P. P.; Remppis, A.; Katus, H. A.; Bierhaus, A. High-mobility group box-1 in ischemia-reperfusion injury of the heart Circulation 2008, 117, 3216-3226
17. Takahashi, K.; Fukushima, S.; Yamahara, K.; Yashiro, K.; Shintani, Y.; Coppen, S. R.; Salem, H. K.; Brouilette, S. W.; Yacoub, M. H.; Suzuki, Ken. Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart Circulation 2008, 118, S106-S114
18. Newman, D. J.; Cragg, G. M.; Snader, K. M. The influence of natural products upon drug discovery Nat. Prod. Rep. 2000, 17, 215-234
19. Newman, D. J.; Cragg, G. M.; Snader, K. M. Natural products as sources of new drugs over the period 1981-2002 J. Nat. Prod. 2003, 66, 1022-1037
20. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years J. Nat. Prod. 2007, 70, 461-477
21. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the 30 years from 1981-2010 J. Nat. Prod. 2012, 75, 311-335
22. Mollica, L.; Marchis, F. D.; Spitaleri, A.; Dallacosta, C.; Pennacchini, D.; Zamai, M.; Agresti, A.; Trisciuoglio, L.; Musco, G.; Bianchi, M. E. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities Chem. Biol. 2007, 14, 431-441
23. Sitia, G.; Lannacone, M.; Müller, S.; Bianchi, M. E.; Guidotti, L. G. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice J. Leukocyte Biol. 2007, 81, 100-107
24. Baltina, L. A. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine Curr. Med. Chem. 2003, 10, 155-171
25. Hirabayashi, K.; Iwata, S.; Matsumoto, H.; Mori, T.; Shibata, S.; Bara, M.; Ito, M.; Shigeta, S.; Nakashima, H.; Yamamoto, N. Antiviral activities of glycyrrhizin and its modified compounds against human immunodeficiency virus type 1 (HIV-1) and herpes simplex virus type 1 (HSV-1) in vitro Chem. Pharm. Bull. 1991, 39, 112-115
26. Hardman, C. H.; Broadhurst, R. W.; Raine, A. R.; Grasser, K. D.; Thomas, J. O.; Laue, E. D. Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three- and four-dimensional NMR spectroscopy Biochemistry 1995, 34, 16596-16607
27. Weir, H. M.; Kraulis, P. J.; Hill, C. S.; Raine, A. R.; Laue, E. D.; Thomas, J. O. Structure of the HMG box motif in the B-domain of HMG1 EMBO J. 1993, 12, 1311-1319
28. Jones, G. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748
29. Berendsen, H. J. C.; van der Spoel, D.; van Drunen, R. GROMACS: a message-passing parallel molecular dynamics implementation Comput. Phys. Commun. 1995, 91, 43-56
30. Sasaki, Y.; Mizutani, K.; Kasai, R.; Tanaka, O. Solubilizing properties of glycyrrhizin and its derivatives: solubilization of saikosaponin-a, the saponin of Bupleuri Radix Chem. Pharm. Bull. 1988, 36, 3491-3495
31. Östberg, T.; Wähämaa, H.; Palmblad, K.; Ito, N.; Stridh, P.; Shoshan, M.; Lotze, M. T.; Harris, H. E.; Andersson, U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis Arthritis Res. Ther. 2008, 10, R1-R9
32. Yang, H.; Hreggvidsdottir, H. S.; Palmblad, K.; Wang, H. C.; Ochani, M.; Li, J. H.; Lu, B.; Chavan, S.; Rosas-Ballina, M.; Al-Abed, Y.; Akira, S.; Bierhaus, A.; Erlandsson-Harris, H.; Andersson, U.; Tracey, K. J. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 11942-11947
33. Liu, Y. Y.; Cai, W. F.; Yang, H. Z.; Cui, B.; Chen, Z. H; Liu, H. Z.; Yan, J.; Jin, W.; Yan, H. M.; Xin, B. M.; Yuan, B.; Hua, F.; Hu, Z. W. Bacillus calmette-guérin and TLR4 agonist prevent cardiovascular hypertrophy and fibrosis by regulating immune microenviroment J. Immunol. 2008, 180, 7349-7357
34. Cai, W. F.; Zhang, X. W.; Yan, H. M.; Ma, Y. G.; Wang, X. X.; Yan, J.; Xin, B. M.; Lv, X. X.; Wang, Q. Q.; Wang, Z. Y.; Yang, H. Z.; Hu, Z. W. Intracellular or extracellular heat shock protein 70 differentially regulates cardiac remodeling in pressure overload mice Cardiovasc. Res. 2010, 88, 140-149
35. Weiner, S. J; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. K. A new force field for molecular mechanical simulation of nucleic acids and proteins J. Am. Chem. Soc. 1984, 106, 765-784
36. Clark, M.; Cramer, R. D.; Van, O. N. Validation of the general purpose Tripos 5.2 force field J. Comput. Chem. 1989, 10, 982-1012